State of Research
Quality of Conclusions
TBD Papers studying this directly
TBD Companies working on this
Make Blossom Sustainable
Blossom is free to use and will always be.
Supporting Blossom makes this possible. When you support Blossom for €20/month, you get access to our downloadable files, influence over the direction of our 'psychedelics and ...' pages, and future projects.
Our vision is that psychedelics can be used worldwide to better the lives of as many as 450 million people who suffer from mental health problems. Our information hopes to make that vision come to life just a little faster.
Here will be a narrative, readable, summary of the research.
In our literature study we came across the following studies of note. Browse the meta, review, commentary articles for an overview. Check out the individual studies for specific experiments and observations.
The Viability of Microdosing Psychedelics as a Strategy to Enhance Cognition and Well-being - An Early Review
2020 | Bornemann, J.
This paper (2020) reviews the available evidence on psychedelic microdosing. The author concludes that the current literature, although seemingly promising, is methodologically insufficient to allow strong conclusions.
Microdosing psychedelics: More questions than answers? An overview and suggestions for future research
2019 | Erritzoe, D., Knudsen, G. M., Kuypers, K. P. C., Nichols, C. D., Nichols, D. E., Ng, L., Nutt, D. J., Pani, L., Soula, A.
We don't yet know much about the effects of microdosing or have even defined it rigorously. Kuypers and colleagues ask the questions and take the first step in building a framework for a more scientific study of microdosing. Microdosing is defined as the 1) use of a low dose below the perceptual threshold that does not impair ‘normal’ functioning of an individual, 2) a procedure that includes multiple dosing sessions, 3) with the intention to improve well-being and enhance cognitive and/or emotional processes.
A quantitative exploration of the relationships between regular yoga practice, microdosing psychedelics, wellbeing and personality variables
2021| Bettinson, S., Blatchford, E., Bright, S. J., Gringart, E.
This exploratory cross-sectional survey study (n=339) investigated differences in mood and wellbeing between samples of people who either microdose, practice yoga, or engage in neither, in light of personality trait differences in openness, neuroticism, and absorption. Microdosing and yoga practices exhibited complementary effects, as participants who practiced both had the highest absorption score, exhibited higher levels of wellbeing, and had less depression and anxiety, compared to people who either practiced yoga or microdosing, and participants recruited as controls. However, participants were recruited from different population samples, which may bias self-report, and lead to significant differences in age, gender, employment, and education between the conditions.
Exploring the relationship between microdosing, personality and emotional insight: A prospective study
2021| Bright, S. J., Dressler, H. M., Polito, V.
This prospective survey study (n=24) explored the relationship between microdosing, personality change, and emotional awareness. Conscientiousness increased, while neuroticism decreased across these time points and correlated negatively with duration of prior microdosing experience. Extraversion correlated positively with both duration of prior microdosing experience and lifetime number of microdoses.
Self-blinding citizen science to explore psychedelic microdosing
2021| Blemings, A., Carhart-Harris, R. L., Erritzoe, D., Feilding, A., Kartner, L., Nutt, D. J., Rosas, F. E., Szigeti, B.
This self-blinding experiment (n=191) finds that the placebo and microdosing groups both experienced similar improvements in self-rated psychological well-being and cognitive function (e.g. mood, energy, creativity) after four weeks. This study provides more evidence that microdosing benefits can be attributed to expectancy (placebo) effects.
Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing
2021| Balaet, M., Buchborn, T., Carhart-Harris, R. L., Erritzoe, D., Kaertner, L. S., Kettner, H., Roseman, L., Spriggs, M. J., Steinborn, M. B., Timmermann, C.
This prospective survey study (n=81) found that expectancy effects were mostly predictive of microdosing outcomes on reductions in state anxiety, depressive symptoms (at 4-week endpoint), and positive outcomes (e.g. psychological resilience, -connectedness, -flexibility).
Microdosing psychedelics: Motivations, subjective effects and harm reduction
2019| Amada, N., Jungaberle, H., Klein, M., Lea, T., Schecke, H.
This survey study (n=525) found that the motivation for microdosing (psilocybin and LSD) was to mainly to improve mental health, personal development, and cognitive enhancement. Four out of five participants used one or more harm reduction techniques on microdosing days (e.g. not dosing when unwell, no alcohol, avoid driving).
Twenty percent better with 20 micrograms? A qualitative study of psychedelic microdosing self-rapports and discussions on YouTube
2019| Andersson, M., Kjellgren, A.
This qualitative study (n=198) of opinions on microdosing found that they were generally well-tolerated and were used for therapeutic or enhancement purposes. The study analysed 32 videos and the self-report reactions to those videos.
This section compares the research with psychedelics to other therapies, medicines, or treatments.
This section highlights the various measures used and their use in research.
Who are the top researches in this area, the ones who have done the groundbreaking research.
What do we not know at this time? Where are the gaps in our knowledge and are we closing it?
The companies that are actively engaged in researching this topic or (planning to) provide therapy focussed on this topic.
This section highlights everything done outside of academia, from popular press to books and non academic research.